Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Regulus Announces Pricing Of Public Offering Of Common Stock July 19, 2017 Trading In Novo Nordisk A/S Shares By Board Members, Executives And Associated Persons On 8 May 2017 May 8, 2017 4 Solid Biotechs to Load Up on This Month December 3, 2017
Trading In Novo Nordisk A/S Shares By Board Members, Executives And Associated Persons On 8 May 2017 May 8, 2017
